parameters were modeled: the first for CYP2A*9, the second for CYP2A6*1A(51A) and CYP2A6*1B12, and the third for the remaining six haplotypes (*1B, *1B7, *1A(51G), *1H, *1D and *1X2). To display parameter estimates intuitively in terms of relative activities in tables 6 and 7, estimates were normalized by first converting to the phenotype, D2-cotinine/(D2-nicotine + D2-cotinine), by subtracting from 1, so that an estimate of 0 corresponds to zero activity, and then divided by the converted estimate for the reference allele, *1B (0.61), in Table 6, or by the converted estimate for ‘all normal activity alleles’ (0.58) in Table 7. Upper and lower confidence intervals in tables 6 and 7, provided to demonstrate the precision of each parameter estimate, were converted and normalized following the same procedure.
